{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008696","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.913885+00:00","generated_at":"2026-06-07T16:05:21.865745+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sunshine Biopharma annual meeting: directors elected, reverse split up to 1:40 approved","bullets":["All five director nominees elected with >16M votes each; broker non-votes 5.04M.","Ratification of BF Borgers as auditor approved: 20.1M for, 2.45M against.","2023 Equity Incentive Plan approved: 15.9M for, 1.84M against.","Reverse stock split authorized at ratio between 1:2 and 1:40, board discretion on timing.","Advisory vote on executive compensation approved; frequency set at every 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008696","json":"https://secwatch.observer/filing/0001683168-23-008696.json","markdown":"https://secwatch.observer/filing/0001683168-23-008696.md","text":"https://secwatch.observer/filing/0001683168-23-008696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:05:21.865745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"019714340b8fefb5c5d9fd33d6f5d495b63d85e9","claim":"Sunshine Biopharma Inc. shareholders approved Election of directors at the 2023-12-07 meeting.","evidence_excerpt":"At the meeting, (i) Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"1fcfefb93c019866880c2c3542e0cd3306eb878b","claim":"Sunshine Biopharma Inc. shareholders approved Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023 at the 2023-12-07 meeting.","evidence_excerpt":"Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023. FOR AGAINST ABSTAIN 20,099,526 2,452,753 418,180","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"5995b16a9ea379182ef462a54f8d584df64c39a4","claim":"Sunshine Biopharma Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-12-07 meeting.","evidence_excerpt":"Advisory vote on frequency of future advisory votes on executive compensation. 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTE 1,777,275 165,011 15,063,931 923,289 5,040,953","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"67b635a7655e3481d7eeda537f27fe7ae20b3bdc","claim":"Sunshine Biopharma Inc. shareholders approved Approval of the Company’s 2023 Equity Incentive Plan at the 2023-12-07 meeting.","evidence_excerpt":"Approval of the Company’s 2023 Equity Incentive Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 15,915,610 1,842,630 171,266 5,040,953","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"714746c373c1be97b2fe0fdb8c7410979f475491","claim":"Sunshine Biopharma Inc. shareholders approved Advisory vote on executive compensation at the 2023-12-07 meeting.","evidence_excerpt":"Advisory vote on executive compensation. FOR AGAINST ABSTAIN BROKER NON-VOTE 16,196,664 1,516,235 216,607 5,040,953","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"bf17592bfcaa89b4b5179606550c2a9049670768","claim":"Sunshine Biopharma Inc. shareholders approved Approval of a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-2 and not more than 1-for-40 at the 2023-12-07 meeting.","evidence_excerpt":"Approval of reverse stock split. FOR AGAINST ABSTAIN 20,005,507 2,657,164 307,788","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}